rAAV vector-mediated gene therapy for experimental ischemic stroke

Neurology India

Volumn 56, Issue 2, 2008, Pages 116-121

  Li, Zhao Jian ^a   Wang, Ren Zhi ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Gene therapy; Ischemic stroke; Recombinant adeno associated virus; Vector

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1 INTERACTING PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DOUBLE STRANDED DNA; DYSTROPHIN; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROGLOBIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PROTEIN; PROTEIN BCL 2; PROTEIN BCL W; SCATTER FACTOR; SINGLE STRANDED DNA; VASCULOTROPIN; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS TYPE 1; ADENO ASSOCIATED VIRUS TYPE 2; ADENO ASSOCIATED VIRUS TYPE 5; ADENO ASSOCIATED VIRUS TYPE 8; ANGIOGENESIS; ANGIOGENIC GENE THERAPY; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; EXCITOTOXICITY; GENE CASSETTE; GENE EXPRESSION; GENE TRANSFER; GLUCOSE TRANSPORT; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; REVIEW; RISK BENEFIT ANALYSIS; SEROTYPE; TRANSGENE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HUMANS; ISCHEMIA; RECOMBINANT FUSION PROTEINS; STROKE;

EID: 47949087638     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.41986     Document Type: Review

References (51)

1. Green AR, Shuaib A. Therapeutic strategies for the treatment of stroke. Drug Discov Today 2006;11:681-93.
2. Ooboshi H, Ibayashi S, Takada J, Kumai Y, Iida M. Brain ischemia as a potential target of gene therapy. Exp Gerontol 2003;38:183-7.
3. Takeda S, Takahashi M, Mizukami H, Kobayashi E, Takeuchi K, Hakamata Y, et al. Successful gene transfer using adeno-associated virus vectors into the kidney: Comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo. Nephron Exp Nephrol 2004;96:119-26.
4. Grimm D, Kay MA. From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003;3:281-304.
5. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2 and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-17.
6. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006;138:501-10.
7. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998;72:1438-45.
8. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 1999;5: 78-82.
9. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999;5:71-7.
10. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adenoassociated virus vectors. J Virol 2000;74: 2777-85.
11. Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 1998;9: 1181-6.
12. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999;73:10371-6.
13. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 2000;74:9184-96.
14. Evans CH, Gouze E, Gouze JN, Robbins PD, Ghivizzani SC. Gene therapeutic approaches-transfer in vivo. Adv Drug Deliv Rev 2006;58: 243-58.
15. Leker RR, Soldner F, Velasco I, Gavin DK, Androutsellis-Theotokis A, McKay RD. Long-lasting regeneration after ischemia in the cerebral cortex. Stroke 2007;38:153-61.
16. Warnock JN, Merten OW, Al-Rubeai M. Cell culture processes for the production of viral vectors for gene therapy purposes. Cytotechnology 2006;50:141-62.
17. Howell JM. Is there a future for gene therapy? Neuromuscul Disord 1999;9:102-7.
18. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003;10:2105-11.
19. Shen F, Su H, Fan Y, Chen Y, Zhu Y, Liu W, et al. Adeno-associated viral-vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice. Stroke 2006;37:2601-6.
20. Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2005;2:120-8.
21. Henderson CE, Camu W, Mettling C, Gouin A, Poulsen K, Karihaloo M, et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature 1993;363:266-70.
22. Roussa E, Krieglstein K. GDNF promotes neuronal differentiation and dopaminergic development of mouse mesencephalic neurospheres. Neurosci Lett 2004;361:52-5.
23. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrests of motor neuron disease in Wobbler mice cotreated with CNTF and BDNF. Science 1994;265:1107-10.
24. Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature 1992;360:753-55.
25. Tsukahara T, Yonekawa Y, Tanaka K, Ohara O, Wantanabe S, Kimura T, et al. The role of brain-derived neurotrophic factor in transient forebrain ischemia in the rat brain. Neurosurgery 1994;34:323-31.
26. Andsberg G, Kokaia Z, Klein RL, Muzyczka N, Lindvall O, Mandel RJ. Neuropathological and behavioral consequences of adeno-associated viral vector-mediated continuous intrastriatal neurotrophin delivery in a focal ischemia model in rats. Neurobiol Dis 2002;9:187-204.
27. Gustafsson E, Andsberg G, Darsalia V, Mohapel P, Mandel RJ, Kirik D, et al. Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke. Eur J Neurosci 2003;17:2667-78.
28. Larsson E, Mandel RJ, Klein RL, Muzyczka N, Lindvall O, Kokaia Z. Suppression of insult-induced neurogenesis in adult rat brain by brain-derived neurotrophic factor. Exp Neurol 2002;177:1-8.
29. Kobayashi T, Ahlenius H, Thored P, Kobayashi R, Kokaia Z, Lindvall O. Intracerebral infusion of glial cell line-derived neurotrophic factor promotes striatal neurogenesis after stroke in adult rats. Stroke 2006;37:2361-7.
30. Airaksinen MS, Saarma M. The GDNF family:signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-94.
31. Arvidsson A, Kokaia Z, Airaksinen MS, Saarma M, Lindvall O. Stroke induces widespread changes of gene expression for glial cell line-derived neurotrophic factor family receptors in the adult rat brain. Neuroscience 2001;106:27-41.
32. Wang Y, Lin SZ, Chiou AL, Williams LR, Hoffer BJ. Glial cell linederived neurotrophic factor protects against ischemia-induced injury in the cerebral cortex. J Neurosci 1997;17:4341-8.
33. Tsai TH, Chen SL, Chiang YH, Lin SZ, Ma HI, Kuo SW, et al. Recombinant adeno-associated virus vector expressing glial cell line-derived neurotrophic factor reduces ischemia-induced damage. Exp Neurol 2000;166:266-75.
34. Arvidsson A, Kirik D, Lundberg C, Mandel RJ, Andsberg G, Kokaia Z, et al. Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiol Dis 2003;14:542-56.
35. Shimazaki K, Urabe M, Monahan J, Ozawa K, Kawai N. Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: Prospects for gene therapy of ischemia-induced neuronal death. Gene Ther 2000;7:1244-9.
36. Okada T, Shimazaki K, Nomoto T, Matsushita T, Mizukami H, Urabe M, et al. Adeno-associated viral vector-mediated gene therapy of ischemia-induced neuronal death. Met Enzymol 2002;346:378-93.
37. Sun Y, Jin K, Clark KR, Peel A, Mao XO, Chang Q, et al. Adeno-associated virus-mediated delivery of BCL-w gene improves outcome after transient focal cerebral ischemia. Gene Ther 2003;10:115-22.
38. Wang YQ, Guo X, Qiu MH, Feng XY, Sun FY. VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion. J Neurosci Res 2007;85:740-7.
39. Kaya D, Gürsoy-Ozdemir Y, Yemisci M, Tuncer N, Aktan S, Dalkara T. VEGF protects brain against focal ischemia without increasing bloodbrain permeability when administered intracerebroventricularly. J Cereb Blood Flow Metab 2005;25:1111-8.
40. Bellomo M, Adamo EB, Deodato B, Catania MA, Mannucci C, Marini H, et al. Enhancement of expression of vascular endothelial growth factor after adeno-associated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil. Pharmacol Res 2003;48:309-17.
41. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000;106:829-38.
42. van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 1999;104:1613-20.
43. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, et al. VEGF-induced neuroprotection, neurogenesis and angiogenesis after focal cerebral ischemia. J Clin Invest 2003;111:1843-51.
44. Tsai TH, Chen SL, Xiao X, Chiang YH, Lin SZ, Kuo SW, et al. Gene treatment of cerebral stroke by rAAV vector delivering IL-1ra in a rat model. Neuroreport 2003;14:803-7.
45. Sun Y, Jin K, Peel A, Mao XO, Xie L, Greenberg DA. Neuroglobin protects the brain from experimental stroke in vivo. Proc Natl Acad Sci USA 2003;100:3497-500.
46. Cao G, Xiao M, Sun F, Xiao X, Pei W, Li J, et al. Cloning of a novel Apaf-1-interacting protein:a potent suppressor of apoptosis and ischemic neuronal cell death. J Neurosci 2004;24:6189-201.
47. Burger C, Nash K, Mandel RJ. Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther 2005;16:781-91.
48. Ooboshi H, Ibayashi S, Takada J, Yao H, Kitazono T, Fujishima M. Adenovirus-mediated gene transfer to ischemic brain: Ischemic flow threshold for transgene expression. Stroke 2001;32:1043-7.
49. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005;5:323-31.
50. Rivière C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 2006;13:1300-8.
51. Han Z, Zhang S, Li H, Ruan X, Xiao X, Tao W, et al. Expression of recombinant adeno-associated virus in the brain of rats with a focal embolic stroke via carotid artery. Chin Med J (Engl) 2002;115:1170-4.